Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

SCRAS describes galanthamine derivatives

March 24, 1997

Quadramet enters phase I for arthritis

March 21, 1997

FDA clears midazolam for use in children

March 21, 1997

3-D structure of adenylyl cyclase core determined

March 21, 1997

Sagami prepares angiotensin IV agonists

March 21, 1997

Antihyperalgesic effects of bradykinin B2 antagonist from Fujisawa

March 19, 1997

FDA approves Ohmeda's neuromuscular blocking agent

March 19, 1997

BioChem Pharma synthesizes opioid analgesics/NMDA antagonists

March 19, 1997

Cephalon discloses cysteine/serine protease inhibitors

March 19, 1997

Avonex approved by European Commission

March 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...